Epsilon opioid receptor (EOR)

The epsilon opioid receptor is a putative G protein-coupled receptor (GPCR) that was initially proposed to explain the unique pharmacological actions of beta-endorphin that could not be attributed to the mu, delta, or kappa opioid receptors (Tseng, 2001; Wikipedia). Although it has been extensively characterized in pharmacological studies, particularly in the rat vas deferens and certain brain regions, a distinct gene encoding the epsilon receptor has not yet been cloned in humans or other mammals (Guide to Pharmacology; Wikipedia). Current evidence suggests that epsilon-mediated effects may arise from splice variants of the mu-opioid receptor (OPRM1) or through the formation of receptor heteromers between known opioid subtypes (Wikipedia; Guide to Pharmacology). Biologically, the epsilon receptor is involved in a specialized descending pain control system; its activation in the brainstem triggers the release of Met-enkephalin in the spinal cord, which then activates delta-2 receptors to produce potent analgesia (Tseng, 2001; Narita et al., 1993). Drugs such as the endogenous peptide beta-endorphin and the synthetic agonist TAN-821 interact with this receptor to induce antinociception, while compounds like buprenorphine and TAN-1014 act as antagonists (Fujii & Nagase, 2006; Wikipedia). Despite its potential as a target for novel analgesics with reduced side effects, the lack of a definitive molecular identity remains a significant challenge for drug development and clinical validation (Guide to Pharmacology).

Other names

epsilon-opioid receptorepsilon receptorputative epsilon opioid receptorbeta-endorphin-sensitive receptorbenzomorphan binding site

Activation of supraspinal epsilon opioid receptors facilitates a descending enkephalinergic pathway, leading to the release of Met-enkephalin in the spinal cord, which subsequently activates spinal delta-2 opioid receptors to produce antinociception (Tseng, 2001; Narita et al., 1993).